{"created":"2023-05-15T14:52:15.198007+00:00","id":71344,"links":{},"metadata":{"_buckets":{"deposit":"cdd4848d-f53c-4242-b06d-c891436938ce"},"_deposit":{"created_by":1,"id":"71344","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"71344"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00071344","sets":["10:28"]},"author_link":["701525","701522","701523","701524","701520","701521"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2013-10-05","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Radionuclide therapy kills tumor cells by the placement of unsealed therapeutic radionuclide in the tumor for the selective delivery of radiation to tumors. Enhanced delivery of therapeutic radionuclide, especially short-range particle emitters, to tumor cell nucleus may induce an increased numbers of lethal DNA damage and cell death, leading to more effective treatment of tumor. Here we report that we generated trastuzumab (Her) modified with nuclear localization signal (NLS) to enhance the delivery of therapeutic radioisotopes to cell nucleus of HER2-overexpressing tumors. A synthetic 13mer peptide including NLS-motif derived from SV40 large T-antigen was attached to Her, a HER2-targeting antibody, by chemical crosslinking. The nuclear localizing Her antibodies (Her-NLS) labeled with auger electron emitters such as iodine-125 were bound to HER2-overexpressing cancer cells and rapidly internalized in the cells. Her-NLS showed enhancement of nuclear localization compared with Her. Nuclear localizing trastuzumab will be useful for HER2-targeting radionuclide therapy using short-range particle emitters such as auger-electron emitters and alpha particle emitters.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第72回日本癌学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hasegawa, Sumitaka"}],"nameIdentifiers":[{"nameIdentifier":"701520","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furukawa, Takako"}],"nameIdentifiers":[{"nameIdentifier":"701521","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saga, Tsuneo"}],"nameIdentifiers":[{"nameIdentifier":"701522","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川 純崇","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"701523","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"古川 高子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"701524","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐賀 恒夫","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"701525","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Generation of nuclear localizing antibody for targeted radionuclide therapy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Generation of nuclear localizing antibody for targeted radionuclide therapy"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-11-14"},"publish_date":"2013-11-14","publish_status":"0","recid":"71344","relation_version_is_last":true,"title":["Generation of nuclear localizing antibody for targeted radionuclide therapy"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:52:20.690843+00:00"}